长江商报消息●长江商报记者 沈右荣战投南京医药(600713.SH),广药集团旗下的白云山(600332.SH)将间接成为南京医药的第二大股东。近期,白云山及南京医药均公告,2025年9月26日,白云山附属企业广州广药二期基金股权投资合伙企业(有限合伙)(简称“广药二期基金”)与相关方签署协议,拟受让南京医药11.04%的股权,交易价款约7.49亿元。白云山为何要入股南京医药?除了通过受让股权成为...
Source Link长江商报消息●长江商报记者 沈右荣战投南京医药(600713.SH),广药集团旗下的白云山(600332.SH)将间接成为南京医药的第二大股东。近期,白云山及南京医药均公告,2025年9月26日,白云山附属企业广州广药二期基金股权投资合伙企业(有限合伙)(简称“广药二期基金”)与相关方签署协议,拟受让南京医药11.04%的股权,交易价款约7.49亿元。白云山为何要入股南京医药?除了通过受让股权成为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.